Showing 2751-2760 of 3039 results for "".
- I-MED Pharma Gains Health Canada Approval For E>Eye Laserhttps://modernod.com/news/i-med-pharma-gains-health-canada-approval-for-eeye-laser/2477656/I-MED Pharma has announced Health Canada approval for dry eye device E>Eye Laser, which is now available to Canadian eye care professionals. E>Eye, designed and manufactured in France by E-Swin, is the only CE certified medical device using patented IRPL technology developed specifi
- WHO Accidently Leaks Disappointing Results of Chinese Clinical Trial Testing Gilead’s Remdesivir in Severe COVID-19https://modernod.com/news/who-accidently-leaks-disappointing-results-of-chinese-clinical-trial-testing-gileads-remdesivir-in-severe-covid-19/2477645/According to a draft document published in error by the World Health Organization (WHO), Gilead Sciences’ remdesivir failed to improve the condition of patients with severe COVID-19 participating in a Chinese clinical trial, nor was the drug found to reduce the virus’ presence in the
- The Tests That Could Reopen the Country: How They Workhttps://modernod.com/news/the-tests-that-could-reopen-the-country-how-they-work/2477614/After weeks of sheltering in place, Americans are asking how soon we can return to a more normal life outside our homes. Much of the answer might be in a test. The first phase of testing has been about determining who has COVID-19. The next phase will be about who had it – or may
- AAO Releases Statement Addressing the Reopening of Ophthalmology Carehttps://modernod.com/news/aao-releases-statement-regarding-returning-to-ophthalmology-practice/2477611/In a letter to its membership, American Academy of Ophthalmology (AAO) CEO David W. Parke II, MD, stated that now is the time to consider the process of reopening ophthalmology care—on a local
- GenSight Biologics Announces Positive Safety Review of PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Treatmenthttps://modernod.com/news/gensight-biologics-announces-positive-safety-review-of-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-treatment/2477583/GenSight Biologics announced that the independent Data Safety Monitoring Board (DSMB) completed its second planned safety review of the ongoing PIONEER phase 1/2 clinical trial of GS030, GenSight’s novel product combining gene therapy and optogenetics for the treatment of retinitis pigmentosa (RP
- AstraZeneca to Study BTK Inhibitor Calquence as Treatment for Cytokine Storm Associated With COVID-19 Infectionhttps://modernod.com/news/astrazeneca-to-study-btk-inhibitor-calquence-as-treatment-for-cytokine-storm-associated-with-covid-19-infection/2477575/AstraZeneca announced that it will investigate the potential of the BTK inhibitor Calquence (acalabrutinib) in the treatment of the cytokine storm associated with COVID-19 infection in severely ill patients. The company noted that the design of the CALAVI study is based on “strong scientifi
- Lilly Partners With NIH to Test Olumiant in Patients Hospitalized With COVID-19https://modernod.com/news/lilly-partners-with-nih-to-test-olumiant-in-patients-hospitalized-with-covid-19/2477574/Drug companies worldwide are testing existing medicines as potential treatments for COVID-19—plus working on new therapeutics—with few answers yet. Now, Eli Lilly is among the latest to kick off a trial through a partnership with federal health officials, according t
- Pfizer Aims to Start Clinical Testing of Lead Compound Against SARS-CoV-2 in Third Quarterhttps://modernod.com/news/pfizer-aims-to-start-clinical-testing-of-lead-compound-against-sars-cov-2-in-third-quarter/2477560/In an update on its efforts to combat COVID-19, Pfizer said results of initial screening assays have led it to zero in on a lead protease inhibitor with antiviral activity against SARS-CoV-2 based on preliminary data. The company stated that it will now perform preclinical testing on the compound
- The Small Business Owner’s Guide to the CARES Acthttps://modernod.com/news/the-small-business-owners-guide-to-the-cares-act/2477547/The programs and initiatives in the Coronavirus Aid, Relief, and Economic Security (CARES) Act that was just passed by Congress are intended to assist business owners with whatever needs they have right now. When implemented, there will be many new resources available for small businesses, as wel
- Mobius Therapeutics Continues Production and Distribution of Mitosolhttps://modernod.com/news/mobius-therapeutics-continues-production-and-distribution-of-mitosol/2477540/Mobius Therapeutics, the maker of Mitosol (mitomycin for solution) 0.2 mg/vial kit for ophthalmic use, has maintained production and inventory of Mitosol, recognizing the nonelective nature of the patient population affected by its intended use. Mitosol is the only FDA approved